When Wall Street Indicts a Cash Flow Machine: Reading CRM Before the May 27 Earnings

Market punished CRM - 41% off 52-week high, ~24% below 200-day - yet trailing 12-month free cash flow was $14.4B on $41.5B revenue, FCF margin 34.7% and cash conversion ~96% Execution metrics support resilience - 3-yr FCF CAGR 31.6%, 5-yr revenue CAGR 14.3%, 3-yr EPS CAGR 26%, last 8 quarters 88% b…

Published: 2026-05-18 by GNG Research

Tickers: CRM, ADBE, NOW, ORCL

Walk into any trading room this week and ask about (CRM). You will hear a confident answer. The franchise is broken. Per-seat pricing is dying. AI is going to eat enterprise software the way streaming ate cable. Starboard already exited. Citi cut the target. The price now sits roughly 24% below its 200-day moving average. The verdict is in, and the company has not even taken the stand. This is the part where I should disagree quietly and move on. Instead, I want to lay the evidence next to the indictment, side by side, and let you decide which one is harder to argue with. Because what I see when I open the cash flow statement is not a dying franchise. I see a company that just generated $14.4 billion in trailing free cash flow on $41.5 billion of revenue, beat consensus EPS by 25% in its last print, raised the dividend for the second time in two years, authorized a fresh $25 billion buyback, and now plans to spend $300 million this year with Anthropic on the very coding tools supposedly threatening its existence. Read in sequence, those moves push directly against the indictment, in a way that resembles a prosecution star witness sabotaging the prosecution's own case.

This is a members-only GNG Research article. Read the full analysis with a GNG Research plan.

More GNG Research articles